Houston, TX (14 August, 2007) CytoGenix, Inc. (CYGX.OB) announced today completion of the first Supply Agreement to provide DNA products to one of its customers. Under the Agreement, the customer will purchase its entire requirements of DNA products from CYTOGENIX for the term of the Agreement. The customer will provide CYTOGENIX with flexible one (1) year and quarterly forecasts representing the customer's needs for multiple key DNA constructs of the type and quantity of DNA products that the customer expects to purchase in each of the next four calendar quarters.
Dr. Yin Chen , Chief Scientific Officer, comments, "Customer recognition of the advantages of our cell-free DNA production platform contrasted with plasmid DNA derived from bacteria is a major contributing factor in attracting this type of repetitive commitment to purchase our synDNATM products."
Dr. Frederic Kendirgi , Senior Scientist overseeing the Company's DNA production platforms, notes, "This Agreement advances the ongoing relationship with our customer, acknowledging our ability to produce and supply DNA material of custom quality and in a timely manner per the customer's request and expectation. We expect this agreement to demonstrate our commitment to foster productive and long term relationships with clients."
Malcolm Skolnick , CEO, states, "This Agreement is a step in the Company's goal toward selling synDNA™ products in the therapeutic market as a replacement for plasmid based DNA products. We will continue our efforts to expand our synDNA™ sales and conclude similar agreements with additional customers."
CytoGenix, Inc. is a Houston-based biopharmaceutical company that develops and markets innovative products and services based on its proprietary synDNATM production and single stranded DNA (ssDNA) expression technology. The company has developed a breakthrough synthetic process for large-scale production of biologically active DNA that can be made faster and cleaner than production using traditional fermentation methods and has developed a novel expression vector that enables production of ssDNA sequences inside target cell. CytoGenix currently holds 13 granted patents and about 57 international or US pending patent applications claiming methods and materials in connection with these platform technologies.
SAFE HARBOR: Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition, and other factors more fully detailed in the company's filings with the Securities and Exchange Commission. Additional information about CytoGenix and its technology can be found on the website at www.cytogenix.com.
Media Contact: Greg Taylor (713) 789-0070
